Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Torimoto K, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ryomoto K, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I; UTOPIA study investigators. Katakami N, et al. Among authors: osonoi t. Diabetes Ther. 2021 Sep;12(9):2499-2515. doi: 10.1007/s13300-021-01125-8. Epub 2021 Aug 6. Diabetes Ther. 2021. PMID: 34357559 Free PMC article.
Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial.
Osonoi T, Shirabe S, Saito M, Hosoya M, Douguchi S, Ofuchi K, Katoh M. Osonoi T, et al. Front Pharmacol. 2023 Jun 7;14:1205021. doi: 10.3389/fphar.2023.1205021. eCollection 2023. Front Pharmacol. 2023. PMID: 37351507 Free PMC article.
Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Osonoi T, Saito M, Hosoya M, Douguchi S, Ofuchi K, Katoh M. Osonoi T, et al. Front Endocrinol (Lausanne). 2023 Jan 11;13:1042061. doi: 10.3389/fendo.2022.1042061. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36714585 Free PMC article.
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
Agarwal R, Tu W, Farjat AE, Farag YMK, Toto R, Kaul S, Lawatscheck R, Rohwedder K, Ruilope LM, Rossing P, Pitt B, Filippatos G, Anker SD, Bakris GL; FIDELIO-DKD and FIGARO-DKD Investigators. Agarwal R, et al. Ann Intern Med. 2023 Dec;176(12):1606-1616. doi: 10.7326/M23-1023. Epub 2023 Dec 5. Ann Intern Med. 2023. PMID: 38048573 Clinical Trial.
Continuous glucose monitoring-derived time in range and CV are associated with altered tissue characteristics of the carotid artery wall in people with type 2 diabetes.
Mita T, Katakami N, Okada Y, Yoshii H, Osonoi T, Nishida K, Shiraiwa T, Kurozumi A, Taya N, Wakasugi S, Sato F, Ishii R, Gosho M, Shimomura I, Watada H. Mita T, et al. Among authors: osonoi t. Diabetologia. 2023 Dec;66(12):2356-2367. doi: 10.1007/s00125-023-06013-3. Epub 2023 Sep 26. Diabetologia. 2023. PMID: 37750893 Free PMC article.
Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study.
Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Yasuda T, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Shimomura I, Watada H. Mita T, et al. Among authors: osonoi t. Sci Rep. 2023 Sep 5;13(1):14649. doi: 10.1038/s41598-023-41036-1. Sci Rep. 2023. PMID: 37669959 Free PMC article.
102 results